Merck Snaps Up Autoimmune-Focused Pandion in Massive $1.85 Billion Deal
Merck said the acquisition adds a pipeline of drug candidates that target a broad range of autoimmune diseases.
The Home of the Life Sciences Industry
Explore Latest News
Cellarity Takes in $123 Million to Drive Cell-Centric Drug Discovery Toward Clinic
The company uses computational modeling of cell behavior to treat disease, instead of going after a molecular target, redefining drug discovery through its cell-centric approach.
- Vitamin C Study Fails to Improve Sepsis Outcomes
- COVID-19 Vaccines Prove Potency in Real-World Studies
- Pharma Industry's Credit Slumps Amidst Pricing Pressures and M&A Activity
- 10x Genomics Announces New Product Lineup and Tetramer Shop Acquisition
- Gene Replacement Therapy-Focused Jaguar and Its Subsidiary Launch with Deerfield-backed Series A
Get personalized job alerts
Create a job alert and receive custom job recommendations straight to your inbox.
Employers
Post jobs on BioSpace and start building your talent pipeline today. Click the button to access our easy eCommerce site, which lets you purchase and post jobs in just a few clicks.